NICE UK actively recommends Sanofi's CD38 monoantigen Sarclisa for the treatment of relapsed/refractic multiple myeloma.
The antibody drug Polivy, which targets CD79a, is recommended by NICE for the treatment of relapsed or resuscable large B-cell lymphoma.
NICE UK has approved for the first time a single anti-Stelara targeting IL-12/IL-23 for the treatment of ulcerative colitis.
NICE gives green light to AstraZeneta's lung cancer treatment Tagrisso after a confidential discount.
The antibody drug Polivy, which targets CD79a, received NICE-recommended treatment for relapsed or incurable large B-cell lymphoma.
Kidney cancer "immune and targeted" first-line treatment! Pfizer and Merck Bavencio and Inlyta combination therapy have been approved by NICE IN!
PD-L1 Single Anti-Bavencio plus Asitini: Recommended by NICE in the UK as a first-line treatment for advanced kidney cancer.
FLT3 inhibitor gilteritinib, recommended by NICE in the UK for the treatment of acute myeloid leukemia.
Another "broad spectrum" cancer drug approved: NICE approves Rozlytrek for all solid tumors used to treat NTRK gene fusion
UK NICE approves first mono-anti-Stelara targeting IL-12/IL-23 for treatment of ulcerative colitis
NICE supports Roche's ALK inhibitor Rozlytrek to treat ROS1-positive non-small cell lung cancer patients
NICE UK approves use of anti-CGRP monoimmune Ajovy to prevent migraines, with patients only need to inject themselves once a month or quarter
NICE UK approves Roche's PD-L1 single anti-Tecentriq treatment for triple-negative breast cancer after offering big discount
Jazz Pharmaceuticals leukemia new drug Vyxeos gets NICE approval
NICE recommends Pfizer Mylotarg in combination with chemotherapy to treat acute myeloid leukemia
NICE approves Bravtovi and Mektovi combination therapy as treatment options for specific types of melanoma patients
NICE recommends Almirall's anti-inflammatory drug Ilumetri (tildrakizumab) for adult patients with plaque-type psoriasis
NICE approves euthanrhus anti-inflammatory drug Cimzia (certolizumab pegol) for treatment of adult patients with plaque psoriasis
NICE approves anti-inflammatory drug Tildrakizumab for treatment of adult patients with moderate to severe plaque psoriasis
NICE recommends Novartis Kisqali and AstraZeneca Faslodex to treat breast cancer patients